Spark Therapeutics Inc. (ONCE) Shares Down 4.5%
Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) were down 4.5% on Tuesday . The stock traded as low as $58.84 and last traded at $61.00, with a volume of 824,134 shares. The stock had previously closed at $63.87.
Several analysts have weighed in on ONCE shares. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research note on Monday, June 13th. Cowen and Company restated a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a research report on Thursday, May 19th. Zacks Investment Research upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a research report on Wednesday, April 20th. Finally, SunTrust Banks Inc. boosted their target price on shares of Spark Therapeutics from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Tuesday, June 21st. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $61.20.
The firm has a 50 day moving average price of $55.24 and a 200-day moving average price of $42.19. The firm’s market cap is $1.82 billion.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Wednesday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. The business had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $1.17 million. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.60) EPS. On average, equities research analysts predict that Spark Therapeutics Inc. will post ($3.81) earnings per share for the current fiscal year.
In other news, major shareholder Hospital Of Philade Children’s sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, June 20th. The shares were sold at an average price of $42.30, for a total value of $42,300,000.00. Following the completion of the transaction, the insider now directly owns 6,768,707 shares in the company, valued at $286,316,306.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Katherine A. High sold 1,890 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $60.00, for a total transaction of $113,400.00. Following the completion of the transaction, the insider now owns 240,000 shares of the company’s stock, valued at $14,400,000. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Spark Therapeutics stock. RS Investment Management Co. LLC boosted its position in shares of Spark Therapeutics Inc. (NASDAQ:ONCE) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,349 shares of the company’s stock after buying an additional 9,957 shares during the period. RS Investment Management Co. LLC owned 1.83% of Spark Therapeutics worth $20,496,000 as of its most recent SEC filing.
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.